Lexaria Bioscience Corp. (LEXX) — SEC Financial Statements & Analysis

Lexaria Bioscience Corp. (LEXX) is a pharmaceutical preparations company, incorporated in NV. Lexaria Bioscience Corp. trades on Nasdaq as: LEXX. Lexaria Bioscience Corp. (LEXX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-05-31, filed with the SEC on 2026-07-13. Based on that filing, Lexaria Bioscience Corp. carries a market cap of $223.83M, a P/E ratio of -28.98x, a P/B ratio of 51.52x, a P/S ratio of 1153.77x, an enterprise value of $220.36M, and an EV/EBITDA multiple of -28.88x. On profitability, it posts a gross margin of 99.61%, an operating margin of -3973.16%, a net margin of -3981.35%, a Return on Equity (ROE) of -162.42%, a Return on Assets (ROA) of -134.06%, and a Return on Invested Capital (ROIC) of -1055.74%. Per share, it reports EPS of $-0.31, diluted EPS of $-0.31, free cash flow per share of $-0.30, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -68.50% year-over-year, net income growth of -32.30% year-over-year, and EPS growth of -46.58% year-over-year. On the balance sheet, it maintains a current ratio of 10.60x, a quick ratio of 9.56x, working capital of $3.68M, a debt-to-equity ratio of 0.10x, a debt ratio of 0.09, an interest coverage ratio of -796.20x, free cash flow of $-7.50M (TTM), and net debt of $-3.48M. Figures sourced from SEC EDGAR.

Market Cap

$223.83M

P/E TTM

-28.98x

EPS TTM

$-0.31

P/B TTM

51.52x

ROE TTM

-162.42%

ROA TTM

-134.06%

Debt To Equity

0.10x

Free Cash Flow TTM

$-7.50M

Net Revenue TTM Growth 1Y

-68.50%

Data as of 2026-05-31 · Source: SEC EDGAR